Apoptosis represents a key anti-cancer therapeutic effector mechanism. During apoptosis, mitochondrial outer membrane permeabilization (MOMP) typically kills cells even in the absence of caspase activity. Caspase activity can also have a variety of unwanted consequences that include DNA damage. We therefore investigated whether MOMP-induced caspase-independent cell death (CICD) might be a better way to kill cancer cells. We find that cells undergoing CICD display potent pro-inflammatory effects relative to apoptosis. Underlying this, MOMP was found to stimulate NF-κB activity through the downregulation of inhibitor of apoptosis proteins. Strikingly, engagement of CICD displays potent anti-tumorigenic effects, often promoting complete tumour regression in a manner dependent on intact immunity. Our data demonstrate that by activating NF-κB, MOMP can exert additional signalling functions besides triggering cell death. Moreover, they support a rationale for engaging caspase-independent cell death in cell-killing anti-cancer therapies.
RESULTS
Mitochondrial permeabilization can engage necroptosis as a form of caspase-independent cell death Mitochondria are not required to execute necroptosis; however, whether they can initiate this type of cell death is unclear 9 . We investigated whether mitochondrial permeabilization could trigger necroptosis as a type of caspase-independent cell death. To induce apoptosis, SVEC cells were treated with the BH3 mimetic ABT-737 with or without the pan-caspase inhibitor Q-VD-OPh. Caspase activity was determined by western blotting for PARP1 cleavage and cell viability was measured by propidium iodide (PI) exclusion. ABT-737 treatment led to PARP1 cleavage that was blocked by Q-VD-OPh treatment (Fig. 1a ). ABT-737 triggered cell death irrespective of caspase inhibition ( Fig. 1b ) but in a MOMP-dependent manner, since MCL-1 expression (which is not effectively inhibited by ABT-737) prevented cell death ( Fig. 1c and Supplementary Fig. 1A -C) 10 . To investigate whether necroptosis could contribute to CICD, we inhibited RIPK1 and RIPK3-two kinases often essential for necroptosis 11 . SVEC cells were treated with ABT-737 with or without Q-VD-OPh together with necrostatin-1 (nec-1), to inhibit RIPK1, or following RIPK3 short hairpin RNA (shRNA) knockdown (Supplementary Fig. 1D ). RIPK3 knockdown prevented necroptosis induced by TNF/zVAD treatment, confirming functional inhibition (Fig. 1d ). Neither nec-1 treatment nor RIPK3 knockdown had any effect on ABT-737-mediated apoptosis (Fig. 1e ). Nevertheless, inhibition of RIPK1 or RIPK3 reduced CICD following BH3-mimetic treatment, demonstrating that necroptosis can be engaged following mitochondrial permeabilization (Fig. 1e ). We investigated this further using BCL-xL-dependent SVEC cells generated using our mito-priming method 12 . SVEC cells expressing GFP-tBID 2A BCL-xL (BCL-xLdependent SVEC cells) were treated with ABT-737 with or without Q-VD-OPh. Alternatively, we used BCL-xL-dependent SVEC cells in which mitochondrial-dependent caspase activity was inhibited by APAF-1 shRNA knockdown 12 . Cell viability was measured using SYTOX Green exclusion and IncuCyte cell imaging. Verifying their BCL-xL survival dependency, ABT-737 treatment led to rapid cell death ( Fig. 1f ) and with expected slower kinetics, in the presence of Q-VD-OPh or following APAF-1 knockdown (Fig. 1f ). Q-VD-OPh treatment completely prevented PARP1, caspase-3, -7 and BID cleavage, confirming effective caspase inhibition ( Fig. 1g and Supplementary Fig. 1E ). Using these cells, we investigated whether necroptosis could contribute to CICD. BCL-xL-dependent SVEC cells were treated with ABT-737 together with Q-VD-OPh and necroptosis was inhibited by nec-1 treatment, RIPK3 knockdown or by CRISPR/Cas9mediated deletion of the essential necroptosis executioner protein MLKL (Fig. 1h-j and Supplementary Fig. 1F-H) . In all cases, cell death was reduced following ABT-737/Q-VD-OPh treatment. Therefore, mitochondrial permeabilization can engage necroptosis as a form of caspase-independent cell death.
MOMP induces TNF synthesis under caspase-deficient conditions
We reasoned that MOMP might trigger necroptosis directly by activating RIPK1/RIPK3 or, indirectly, via TNF signalling. To discriminate these possibilities, SVEC cells were treated to undergo CICD in the presence of nec-1 (to inhibit RIPK1) or Enbrel (TNF-receptor-II/IgG fusion protein) to inhibit TNF signalling. Cell viability was measured by PI exclusion (Fig. 2a ). As before, ABT-737/Q-VD-OPh induced CICD in a nec-1-sensitive manner. Neither Enbrel nor nec-1 treatment impacted on ABT-737-mediated apoptosis ( Fig. 2a ). However, inhibition of TNF signalling by Enbrel treatment reduced cell death following ABT-737/Q-VD-OPh treatment that was not further inhibited by nec-1 treatment ( Fig. 2a ). Similar results were obtained using BCL-xL-dependent SVEC cells (Fig. 2b) . This demonstrates that MOMP-induced necroptosis requires TNF. In a reciprocal manner, exogenous TNF massively enhanced CICD following ABT-737 treatment that was inhibited by either RIPK3 knockdown or nec-1 treatment (Fig. 2c ). Therefore, under caspase-inhibited conditions, MOMP can engage and sensitize to TNF-dependent necroptosis. We asked whether MOMP could trigger TNF synthesis. BCL-xL-dependent SVEC cells were treated with ABT-737 with or without Q-VD-OPh and analysed by quantitative PCR with reverse transcription (qRT-PCR) for Tnf messenger RNA transcript level ( Fig. 2d ). Under caspase-inhibited conditions, ABT-737 treatment led to an increase in Tnf transcript level (Fig. 2d ) in a MOMPdependent manner ( Fig. 2e and Supplementary Fig. 1I ). Using an enzyme-linked immunosorbent assay (ELISA), we also confirmed an increase in extracellular TNF protein level following engagement of CICD ( Fig. 2f ). To extend these findings, we used cells in which mitochondrial-dependent caspase activity was inhibited by APAF-1 knockdown 12 or by CRISPR/Cas9 deletion of caspase-9 (Supplementary Fig. 1J ). In both settings, ABT-737 treatment led to an increase in TNF transcript levels (Fig. 2g,h) . The MOMP-dependent increase of Tnf transcript was necroptosis independent since it was not impacted by MLKL deletion ( Supplementary Fig. 1K ). Finally, we assayed Tnf transcript levels in BCL-xL-dependent mouse embryonic fibroblasts (MEFs) following ABT-737 treatment in the presence of Q-VD-OPh. As in SVEC cells, Tnf mRNA was also increased in MEFs following ABT-737 treatment, dependent on caspase inhibition (Fig. 2i ).
Mitochondrial permeabilization activates NF-κB
Given a major role of TNF in inflammation, we aimed to understand how MOMP could drive inflammatory signals in caspase-deficient settings, hypothesizing that MOMP might activate NF-κB-a key pro-inflammatory transcriptional regulator. BCL-xL-dependent SVEC cells were treated with ABT-737 and NF-κB activation was measured by NF-κB p65 nuclear translocation. Importantly, ABT-737 treatment led to NF-κB activation in a manner that was significantly increased under caspase-deficient conditions ( Fig. 3a,b ). BAX/BAKdeleted SVEC cells failed to activate NF-κB following ABT-737 treatment, demonstrating its MOMP dependence (Fig. 3c,d and Supplementary Fig. 2A ). Inhibiting mitochondrial-dependent caspase activity by APAF-1 shRNA knockdown or by caspase-9 CRISPR/Cas9 deletion also enabled NF-κB activation following ABT-737 treatment ( Supplementary Fig. 2B ,C). Moreover, CRISPR/Cas9-mediated deletion of IKKβ or NEMO (also known as IKKγ) inhibited NF-κB p65 nuclear translocation following ABT-737/Q-VD-OPh treatment ( Supplementary Fig. 2D ,E). Consistent with an ability of MOMP to activate NF-κB, IκBα phosphorylation and degradation was detected following ABT-737 treatment in caspase-deficient settings (Fig. 3e ). Loss of IκBα, but not phosphorylation, was also observed in cells treated with ABT-737 to undergo apoptosis, in Supplementary Fig. 9 . Supplementary Table 5 .
line with IκBα being a reported caspase substrate ( Fig. 3e ) 13 . Using luciferase-based reporter constructs, ABT-737 treatment was also found to increase NF-κB transcriptional activity under caspaseinhibited conditions (Fig. 3f ). Combined ABT-737/Q-VD-OPh treatment also led to NF-κB activation in MEFs and HeLa cells ( Supplementary Fig. 2F ). Importantly, neither Enbrel treatment nor MLKL deletion affected ABT-737/Q-VD-OPh-induced NF-κB p65 translocation, demonstrating that MOMP-induced NF-κB activation is TNF and necroptosis independent ( Supplementary  Fig. 2G ,H). To investigate whether Tnf mRNA upregulation following Supplementary Table 5 . Unprocessed original scans of blots are shown in Supplementary Fig. 9 .
MOMP required NF-κB, we expressed IκB SR (super repressor)-a non-degradable IκBα that inhibits NF-κB nuclear translocation 14 . Inhibition of NF-κB activity by IκB SR expression was verified by inhibition of NF-κB p65 nuclear translocation following MOMP and increased cell death following TNF treatment ( Fig. 3g and Supplementary Fig. 2I ,J). Importantly, IκB SR expression completely prevented Tnf mRNA upregulation following ABT-737 treatment, confirming its NF-κB dependence (Fig. 3h ). IκB SR expression also inhibited cell death following ABT-737/Q-VD-OPh treatment, consistent with a role for MOMP-dependent TNF synthesis in necroptosis engagement ( Supplementary Fig. 2K ). These data demonstrate that under caspase-deficient conditions, MOMP potently activates NF-κB leading to the expression of pro-inflammatory TNF.
MOMP activates NF-κB through IAP downregulation and NIK activation
We next sought to understand how mitochondrial permeabilization could trigger NF-κB activity. Small molecules known as SMAC mimetics can activate NF-κB by causing inhibitor of apoptosis protein (IAP) degradation leading to NF-κB-inducing kinase (NIK) stabilization and activation 15, 16 . Because these molecules mimic the mitochondrial protein SMAC (also known as DIABLO), which is released from mitochondria following MOMP, we hypothesized that MOMP might activate NF-κB through a similar mechanism ( Supplementary Fig. 3A ). BCL-xL-dependent SVEC cells were treated with ABT-737 together with Q-VD-OPh or with SMAC mimetic (SM-83), and cell lysates were probed for cIAP1, NIK and XIAP ( Fig. 4a ). Supporting previous data, SMAC-mimetic (SM-83) treatment led to cIAP1 downregulation and a concomitant increase of NIK ( Fig. 4a) 15, 16 . Phenocopying this effect, combined ABT-737/Q-VD-OPh treatment also triggered cIAP1 loss, NIK upregulation and, additionally, XIAP depletion. cIAP1 and XIAP loss was partially inhibited by the proteasome inhibitor MG132, indicating that they were targeted for proteasomal degradation following MOMP ( Supplementary Fig. 3B ). Similar effects were observed in MEFs and HeLa cells following ABT-737 treatment ( Supplementary Fig. 3C ). Demonstrating a MOMP dependency, combined ABT-737/Q-VD-OPh treatment triggered a loss of cIAP1 and XIAP and an increase in NIK that was completely blocked in BAX/BAK-deleted cells (Fig. 4b ). These data demonstrate that MOMP can signal IAP degradation and NIK upregulation. We investigated whether this was required for MOMP-dependent NF-κB activity by generating NIK-deleted or cIAP2-overexpressing SVEC cells ( Supplementary Fig. 3D ). Cells were treated with ABT-737 in the presence of caspase inhibitor and NF-κB activity was assayed by measuring nuclear translocation of NF-κB p65 ( Fig. 4c and Supplementary Fig. 3E ,F). Following NIK deletion or cIAP2 overexpression, NF-κB activation was strongly suppressed in response to ABT-737/Q-VD-OPh treatment ( Fig. 4c and Supplementary  Fig. 3E,F) . ABT-737/Q-VD-OPh-dependent Tnf mRNA upregulation was also inhibited in NIK-deleted or cIAP2-overexpressing cells (Fig. 4d ). Finally, ectopic cIAP2 expression inhibited upregulation of NIK following ABT-737/Q-VD-OPh treatment (Fig. 4e ). NF-κB transcriptional activity typically occurs following activation of either the canonical or the non-canonical (alternative) pathway. Our results support canonical NF-κB activation following MOMP; however, given the well-established association between NIK with non-canonical NF-κB activity, we investigated non-canonical NF-κB activity following MOMP. Consistent with non-canonical pathway activation following MOMP, increased NF-κB p100 to p52 processing was observed following ABT-737/QVD treatment ( Supplementary Fig. 3G ). Nevertheless, inhibiting non-canonical NF-κB activity (by deleting p100 or RelB) did not block canonical NF-κB activation following MOMP ( Supplementary Fig. 3H-J) . These data support a model that MOMP signals NF-κB activation in a manner analogous to SMAC mimetics. We therefore investigated the dependence of these effects on endogenous SMAC and OMI (a mitochondrial protein that also binds IAP proteins following MOMP). E1A/Ras-transformed wild-type MEFs or SMAC −/− OMI −/− MEFs were treated with a combination of ABT-737 and UMI-77 (MCL-1 inhibitor) to engage MOMP, and cIAP1 levels were measured ( Fig. 4f) 17, 18 . cIAP1 was depleted to a similar extent in both cell lines, demonstrating that cIAP1 degradation neither requires SMAC or OMI. Similarly, combined knockdown of SMAC and OMI did not rescue cIAP1 or XIAP loss following ABT-737/Q-VD-OPh treatment ( Supplementary Fig. 3K ). Accordingly, wild-type MEFs and SMAC −/− OMI −/− MEFs activated NF-κB to a similar extent following MOMP ( Fig. 4g ). Besides SMAC and OMI, other mitochondrial proteins can bind IAP proteins 19, 20 . Because these could potentially mediate IAP degradation, we investigated whether MOMP could trigger IAP degradation by a SMAC-like mechanism. XIAP or an XIAP point mutant (XIAP D214S E314S ) unable to bind SMAC was expressed in BCL-2-dependent HeLa cells, and cells were treated to undergo MOMP (Fig. 4h) 21 . While XIAP was rapidly degraded following ABT-263/Q-VD-OPh treatment, the XIAP mutant unable to bind SMAC was completely stabilized. This supports a model whereby IAP proteins are degraded by a SMAC-like mechanism following MOMP leading to NIK and NF-κB activation.
Mitochondrial permeabilization activates an NF-κB-dependent pro-inflammatory response
We investigated whether mitochondrial permeabilization could induce additional pro-inflammatory cytokines besides TNF. BCL-xLdependent SVEC cells were treated with ABT-737 with or without Q-VD-OPh and culture supernatant was assayed for cytokine levels ( Fig. 5a and Supplementary Fig. 4A ). Several cytokines tested including MCP-1, KC, IL-6, TNF and IL-12 were upregulated following ABT-737 treatment dependent on caspase inhibition ( Fig. 5a and Supplementary Fig. 4A ). To investigate the NF-κB dependence of this pro-inflammatory signature, SVEC cells expressing IκB SR were treated with ABT-737 together with Q-VD-OPh. NF-κB inhibition silenced most cytokines analysed following ABT-737/Q-VD-OPh treatment ( Fig. 5b and Supplementary Fig. 4B ). Similarly, qRT-PCR analysis also revealed NF-κB-dependent transcriptional upregulation of various cytokines following ABT-737/Q-VD-OPh treatment (Fig. 5c ). Pro-inflammatory cytokine upregulation following MOMP was not inhibited in MLKL-deleted cells, demonstrating its necroptosis independence ( Supplementary Fig. 4C ). Canonical NF-κB activity alone was required for MOMP-induced cytokine upregulation (Supplementary Fig. 4D-H) . Importantly, mitochondrial permeabilization has recently been found to trigger a type I interferon response dependent on mitochondrial DNA (mtDNA) activating the cGAS/STING Supplementary Table 5 . Unprocessed original scans of blots are shown in Supplementary Fig. 9 . Supplementary Table 5 . Unprocessed original scans of blots are shown in Supplementary Fig. 9 .
signalling pathway 22, 23 . We therefore asked whether MOMP-induced NF-κB activity also contributed to the interferon response. SVEC cells expressing IκB SR were treated with ABT-737 together with Q-VD-OPh and an interferon response gene signature was assayed by qRT-PCR ( Fig. 5d ). As controls, STING signalling was inhibited by CRISPR/Cas9 STING deletion or by using mtDNA-depleted ρ 0 SVEC cells ( Supplementary Fig. 4I,J) . Consistent with the findings of others, inhibition of cGAS/STING signalling effectively blocked the interferon transcriptional response following MOMP (Supplementary Fig. 4K,L) 22, 23 . Significantly, suppressing NF-κB activity by IκB SR expression also inhibited the interferon transcriptional response (Fig. 5d ). Given this, we investigated the relationship between MOMPinduced NF-κB and STING activities. NF-κB activity was measured by monitoring NF-κB p65 nuclear translocation following ABT-737/Q-VD-OPh treatment in STING-deleted or ρ 0 SVEC cells (Fig. 5e ). MOMP-induced NF-κB activity was unaffected in STING-deleted and ρ 0 cells, demonstrating that MOMP-induced NF-κB activity requires neither mtDNA nor STING. In agreement, cIAP1 was still degraded following MOMP in both ρ 0 and STING-deleted SVEC cells following ABT-737/Q-VD-OPh treatment (Fig. 5f ). Finally, we investigated whether MOMP-dependent NF-κB transcriptional targets also required STING signalling. STING-deleted SVEC cells were treated with ABT-737 together with Q-VD-OPh and cytokine transcript levels were measured by qRT-PCR (Fig. 5g ). Interestingly, while some NF-κB-dependent transcriptional targets were affected by STING deletion (Mcp-1, Tnf ) others (Kc, Gm-csf ) were not (Fig. 5g ), highlighting a differential requirement for STING activity following MOMP.
MOMP-dependent NF-κB signalling within dying cells promotes macrophage activation
We next investigated whether engaging mitochondrial apoptosis versus CICD could elicit different paracrine effects. BCL-xLdependent SVEC cells were incubated with ABT-737 with or without Q-VD-OPh and culture supernatant was transferred to primary bonemarrow-derived macrophages (BMDMs). Macrophage activation towards an M1, pro-inflammatory or an M2, anti-inflammatory state was assayed by qRT-PCR for transcripts characteristic of either state (Fig. 6a ). Importantly, media from cells undergoing CICD promoted macrophage activation towards an M1 phenotype, as determined by an increase in M1-associated transcript levels, whereas no effect was observed using media from apoptotic cells (Fig. 6a ). Consistent with this, BMDMs incubated with media from cells undergoing CICD also displayed an increase in the M1-associated marker CD86 (Fig. 6b ). Media transferred from SVEC cells undergoing CICD following APAF-1 knockdown or caspase-9 deletion also activated macrophages towards an M1 phenotype ( Fig. 6c and Supplementary Fig. 5A,B ). These effects required MOMP but not necroptosis, since media transferred from ABT-737/Q-VD-OPhtreated BAX/BAK-deleted cells failed to activate macrophages whereas media from MLKL-deleted cells still activated macrophages ( Fig. 6d and Supplementary Fig. 5C,D) . Significantly, NF-κB inhibition (through IκB SR expression) completely prevented the ability of cells undergoing CICD to promote M1 polarization (Fig. 6e ). Inhibiting MOMP-dependent NF-κB activation by deletion of NIK, NF-κB p65 or NEMO or by cIAP2 overexpression also had inhibitory effects ( Supplementary Fig. 5E-H) . These results demonstrate that the ability of CICD to promote M1-macrophage polarization requires MOMPdependent NF-κB activity. Because M1 macrophages are associated with anti-tumorigenic properties 24 we asked whether tumour cells undergoing CICD could also activate macrophages towards an M1 profile. Primary tumour cells were isolated from a Myc-driven mouse model of pancreatic ductal adenocarcinoma (PDAC) and treated with ABT-737 together with Q-VD-OPh. Consistent with MOMPdependent transcriptional upregulation, TNF and IFNβ transcript levels increased following treatment ( Supplementary Fig. 5I ). Culture supernatant was transferred to primary BMDMs and the macrophage activation state was determined by qRT-PCR and flow cytometry ( Fig. 6f,g) . Under CICD conditions, media from PDAC cells also promoted polarization of macrophages towards an M1 state (Fig. 6f,g) . We investigated what factor(s) produced by cells undergoing CICD could promote macrophage activation, focusing initially on TNF. SVEC cells were treated to undergo CICD and medium was transferred to wild-type macrophages with or without Enbrel or to BMDMs derived from Tnfr-1 −/− mice and macrophage activation was assessed ( Supplementary Fig. 5J,K) . In both cases, TNF signalling inhibition abrogated but did not abolish macrophage activation. Given this, coupled to our finding and that of others 22,23 that cells undergoing CICD produce IFNβ led us to carry out similar experiments in the presence of neutralizing IFNβ antibody. IFNβ neutralization either alone or in combination with Enbrel (to block TNF) also inhibited macrophage activation ( Supplementary Fig. 5L ) to some extent, demonstrating that TNF and IFNβ contribute to CICD-induced macrophage activation. These data show that apoptosis and CICD can exert differential paracrine effects. Importantly, cells undergoing CICD can promote macrophage inflammatory activation towards a potentially antitumorigenic phenotype that requires MOMP-driven NF-κB activity.
Caspase-independent cell death displays potent anti-tumorigenic effects
Our findings suggest that under caspase-deficient conditions, MOMPdependent NF-κB activity could confer therapeutic benefit in cancer treatment. To test this, we performed tumour allograft and treatment experiments using the colorectal cancer line CT26. These cells are RIPK3 deficient, allowing investigation of anti-tumorigenic CICD effects in the absence of necroptosis 25 . CT26 cells were transduced with GFP-tBID 2A BCL-2-encoding retrovirus to generate a heterogeneous population of BH3-mimetic-sensitive and -resistant cells. These were either caspase-proficient or rendered deficient in MOMPinduced caspase activity through APAF-1 knockdown ( Supplementary  Fig. 6A ). BH3-mimetic treatment induced a similar extent of MOMP in the presence or absence of APAF-1 ( Supplementary Fig. 6A ). Cells were subcutaneously injected into BALB/c mice as syngeneic hosts. Following tumorigenesis, mice were treated with the BH3 mimetic ABT-263 (the orally available bioequivalent of ABT-737) to induce either tumour-cell apoptosis or CICD ( Supplementary Fig. 6B ).
Caspase activity was detectable only under apoptotic conditions, as confirmed by immunohistochemical staining for active caspase-3 ( Supplementary Fig. 6C ). Supporting our in vitro data, Luminex assay revealed increased systemic cytokine levels; the majority of them pro-inflammatory, under conditions where tumour-specific CICD had been engaged ( Fig. 7a and Supplementary Fig. 6D ). We Supplementary Table 5 .
next investigated immune cell infiltration into tumours after CICD induction or apoptosis. While total macrophage infiltration was similar following either CICD or apoptosis ( Supplementary Fig. 6E ), areas of macrophage accumulation were prevalent in tumours permissive only for CICD ( Supplementary Fig. 6F ). Importantly, highly granulated macrophages expressed significant levels of MHC-II but not CD206, where CICD had specifically been triggered, mirroring the in vitro pro-inflammatory status observed previously ( Supplementary Fig. 6G,H ). An increase in T-cell infiltration was specifically observed following engagement of tumour-cell CICD (Fig. 7b,c) . Together with our previous results, these data argue that CICD may be more immunogenic than apoptosis. On this basis, we directly addressed a possible therapeutic benefit of engaging tumour-specific CICD compared with apoptosis. BCL-2-dependent control or APAF-1-knockdown CT26 cells were subcutaneously injected into BALB/c mice. Once tumours were established, mice were treated four times with ABT-263 over a two-week period and tumour growth was monitored (Fig. 7d ). In the presence of vehicle alone, APAF-1-knockdown tumours grew slower than their wild-type counterparts. Tumour growth was unaffected by ABT-263 engagement of apoptosis; however, under CICD conditions, ABT-263 treatment led to a significant overall reduction in tumour growth (Fig. 7d ). Further analysis revealed complete regression in 50% of mice bearing APAF-1-knockdown tumours, following ABT-263 treatment (Fig. 7e) . These data show that engaging CICD in tumours elicits inflammatory and immune effects. Most importantly, CICD displays potent anti-tumour effects, frequently leading to complete tumour regression.
CICD anti-tumorigenic effects require NF-κB and intact immunity
Because engaging tumour CICD can lead to complete tumour regression, we investigated the role of immunity in mediating these effects.
As for before, BCL-2-dependent control or APAF-1-knockdown CT26 cells were subcutaneously injected into BALB/c mice. Following tumour establishment, mice were treated four times with ABT-263 over a two-week period. Tumours were isolated at a defined endpoint, and then analysed by flow cytometry for tumourinfiltrating immune cells. Tumours displaying regression or outgrowth were termed as responders or non-responders respectively. Consistent with earlier results, APAF-1-knockdown tumours displayed the most effective response following ABT-263 treatment (Supplementary Fig. 7A ). Importantly, ABT-263 treatment led to an increase in total macrophage infiltration (F4/80 + ) as well as an enhancement of activated, anti-tumorigenic macrophage subsets (NOS2 + , CD86 + , MHC-II + ) in tumours responding to CICD (APAF-1 SH ) ( Fig. 8a and Supplementary Fig. 7B ). Analysis of tumour-infiltrating T cells revealed an increase in total T-cell infiltrate, comprised of increased CD4 + T-helper cells and cytotoxic CD8 + T cells specifically in tumours responding to CICD (APAF-1 SH ) ( Supplementary  Fig. 7C ). Furthermore, an increase in IFNγ + CD4 + T-helper cells, consistent with activation of an anti-tumorigenic Th1 response, and activated cytotoxic CD8 + cells (IFNγ + , GZMB + , IFNγ + /GZMB + ), was identified in tumours responding to CICD (Fig. 8b,c) . These results demonstrate that an anti-tumorigenic immune activation correlates with response following CICD engagement. We therefore hypothesized that the beneficial effects of engaging CICD might be due to an ability of the immune system to control tumour growth. To test this, BCL-2-dependent control or APAF-1knockdown CT26 cells were subcutaneously injected into immunocompromised NOD scid gamma c −/− (NSG) mice. Following tumour establishment, mice were left untreated or repeatedly treated with ABT-263 and tumour growth was monitored ( Fig. 8d and Supplementary Fig. 7D ). Importantly, ABT-263 treatment had no effect on tumour growth in NSG mice, thereby supporting a key role for the immune system in mediating the anti-tumorigenic effects of CICD. APAF-1-knockdown tumours grew with similar kinetics to wild-type tumours in NSG mice ( Supplementary Fig. 7D ), unlike their slower growth in immuncompetent BALB/c mice (Fig. 7d ). This may be due to a basal level of CICD activating growthinhibitory anti-tumour immunity. We carried out similar experiments under T-cell-depleted conditions. BCL-2-dependent APAF-1 knockdown CT26 cells were subcutaneously injected into BALB/c mice. Once tumours were established, mice were treated with ABT-263 and T-cell-depleting antibody (anti-Thy.1) or isotype control over a two-week period and tumour growth was monitored. Anti-Thy.1 treatment effectively depleted T cells ( Supplementary Fig. 7E,F) and robustly inhibited the anti-cancer effects of engaging CICD, completely preventing tumour regression ( Fig. 8e and Supplementary  Fig. 7G ). We addressed whether the anti-cancer effects of engaging CICD were dependent on MOMP-induced NF-κB activation. NF-κBproficient (vector) and -deficient (NEMO SH ) BCL-2-dependent APAF-1 knockdown CT26 cells were subcutaneously injected into BALB/c mice ( Supplementary Fig. 7H ). Following tumour formation, mice were treated with the BH3 mimetic ABT-263 to induce tumourcell CICD and tumour growth was monitored (Fig. 8f) . Importantly, while ABT-263 CICD engagement promoted complete tumour regression, blocking NF-κB signalling through NEMO knockdown inhibited these effects ( Fig. 8f and Supplementary Fig. 7I ). Finally, we examined the potential clinical relevance of our findings by interrogating the Cancer Proteome Atlas (TCPA) 26 . We investigated the relationship between NF-κB, caspase activity and treatment outcome in renal cell carcinoma. Phospho-NF-κB p65 S536 and cleaved caspase 7 were used as measures of NF-κB and caspase activity (Fig. 8g ). In line with our data, an inverse correlation between NF-κB activity and caspase-7 activity was found ( Fig. 8g ). Importantly, high levels of NF-κB activity and low levels of caspase-7 activity also correlated with improved prognosis following therapy (Fig. 8g) . These data show that CICD is an immunogenic form of cell death, and that both NF-κB activity during CICD and immunity are required for its anti-tumorigenic effects.
DISCUSSION
As others have reported 27 , progressive mitochondrial dysfunction that ensues post-MOMP under caspase-inhibited conditions leads to cell death. Nevertheless, our data demonstrate that how MOMP kills-either by apoptosis or CICD-has profoundly different effects. Unlike mitochondrial apoptosis, cells undergoing CICD display a proinflammatory phenotype dependent on NF-κB activity in the dying cell. Importantly, recent studies have shown that MOMP can also activate cGAS/STING signalling dependent on mtDNA 22, 23 . While we find that MOMP-dependent NF-κB activation and cGAS/STING signalling are independent events, both are required for the collective pro-inflammatory effects of CICD. From our data, we propose a model that MOMP activates NF-κB in a manner similar to small-molecule SMAC mimetics. NF-κB is typically anti-apoptotic 28 ; moreover, IKK activity can also promote survival through NF-κB-independent means 29 . Nevertheless, because widespread MOMP represents a terminal event, NF-κB or IKK activation post-MOMP will not allow long-term cell survival. Our results demonstrate that NIK-dependent canonical NF-κB activity is important for the inflammatory and anti-tumour effects we observe. While NIK is best associated with activation of non-canonical NF-κB activity, it has also been shown to crosstalk with canonical NF-κB activity [30] [31] [32] . Indeed, SMAC mimetics also activate canonical NF-κB signalling in a manner that can depend on NIK 15, 16, 33 . The failure of NIK deletion to completely prevent NF-κB signalling following MOMP suggests that additional MOMP-dependent pathways may also signal NF-κB activity.
Importantly, triggering CICD but not apoptosis often led to complete tumour regression. Especially under conditions of partial therapeutic response, as our experiments mimic, these data suggest Post-treatment days 0 2 5 7 9 12 14 16 19 21 23 Post-treatment days 0 2 5 7 9 12 14 16 19 21 23 Post-treatment days Tumour-bearing mice were pre-treated with isotype control or anti-Thy.1. One day later mice were treated with vehicle or ABT-263 (black arrowheads indicate treatment points) together with isotype control or anti-Thy.1 (red arrowheads indicate treatment points). Tumour growth was monitored every other day. APAF-1 SH + Isotype ctrl + ABT-263, n = 10 mice; APAF-1 SH + anti-Thy.1 + ABT-263, n = 9 (±s.e.m.). (f) BCL-2-dependent APAF-1 SH CT26 cells and expressing vector or NEMO shRNA were injected into mice. Tumour-bearing mice were treated with vehicle or ABT-263. Individual mouse tumour growth is shown. Post-treatment, each tumour was normalized (%) to the initial tumour volume (each set at 100%). Arrowheads indicate time of treatment and crosses indicate tumours that grew over 500% of the initial volume. APAF-1 SH -vector + vehicle, n = 9 mice; APAF-1 SHvector + ABT-263, n = 10; APAF-1 SH -NEMO SH + vehicle, n = 8; APAF-1 SH -NEMO SH + ABT-263, n = 8. (g) In silico analysis of clinical data from renal cell carcinoma patients using the TCPA database. * P < 0.05, * * P < 0.01; Dunn's-corrected Kruskal-Wallis (a-c), Tukey-corrected two-way ANOVA (e), Spearman's rank test (correlation), Cox and log-rank test (Kaplan-Meier curves) (g).
that triggering tumour-specific CICD rather than apoptosis may be a more effective way to treat cancer. Indeed, others have also observed enhanced anti-tumorigenic effects treating tumour cells with cytotoxic agents together with caspase inhibitor 34, 35 . From our data, we reason that CICD is more immunogenic than apoptosis and that this contributes to its increased anti-tumour activity. Mirroring our findings, NF-κB activity has recently been shown to be a key immunogenic determinant of necroptotic cell death that is essential for anti-tumour immunity 36 . While necroptosis is not important for the anti-tumour effects of CICD, NF-κB activation is. Because many cancers are resistant to necroptosis 37 , this significantly broadens the potential utility of targeting CICD in cancer. Importantly, caspase activity is neither required for MOMP-dependent cell death and indeed can have unwanted effects 4 . Coupled to our own findings, we propose that engaging CICD as a means of anti-cancer therapy warrants further investigation.
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